These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 38643482)

  • 61. Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.
    Singh K; Munuganti RSN; Lallous N; Dalal K; Yoon JS; Sharma A; Yamazaki T; Cherkasov A; Rennie PS
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462880
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.
    Fanning SW; Mayne CG; Dharmarajan V; Carlson KE; Martin TA; Novick SJ; Toy W; Green B; Panchamukhi S; Katzenellenbogen BS; Tajkhorshid E; Griffin PR; Shen Y; Chandarlapaty S; Katzenellenbogen JA; Greene GL
    Elife; 2016 Feb; 5():. PubMed ID: 26836308
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
    Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
    Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
    Grinshpun A; Sandusky ZM; Jeselsohn R
    Hematol Oncol Clin North Am; 2023 Feb; 37(1):169-181. PubMed ID: 36435608
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
    Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
    J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
    Yu L; Wang L; Mao C; Duraki D; Kim JE; Huang R; Helferich WG; Nelson ER; Park BH; Shapiro DJ
    Cancer Lett; 2019 Feb; 442():373-382. PubMed ID: 30419347
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeting the IRE1-XBP1 axis to overcome endocrine resistance in breast cancer: Opportunities and challenges.
    Barua D; Gupta A; Gupta S
    Cancer Lett; 2020 Aug; 486():29-37. PubMed ID: 32446861
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.
    Magnani L; Frige G; Gadaleta RM; Corleone G; Fabris S; Kempe MH; Verschure PJ; Barozzi I; Vircillo V; Hong SP; Perone Y; Saini M; Trumpp A; Viale G; Neri A; Ali S; Colleoni MA; Pruneri G; Minucci S
    Nat Genet; 2017 Mar; 49(3):444-450. PubMed ID: 28112739
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
    Fanning SW; Jeselsohn R; Dharmarajan V; Mayne CG; Karimi M; Buchwalter G; Houtman R; Toy W; Fowler CE; Han R; Lainé M; Carlson KE; Martin TA; Nowak J; Nwachukwu JC; Hosfield DJ; Chandarlapaty S; Tajkhorshid E; Nettles KW; Griffin PR; Shen Y; Katzenellenbogen JA; Brown M; Greene GL
    Elife; 2018 Nov; 7():. PubMed ID: 30489256
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
    Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG
    Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
    Kim SS; Lee MH; Lee MO
    Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 73. ESR1 mutations: a new biomarker in breast cancer.
    Carausu M; Bidard FC; Callens C; Melaabi S; Jeannot E; Pierga JY; Cabel L
    Expert Rev Mol Diagn; 2019 Jul; 19(7):599-611. PubMed ID: 31188645
    [No Abstract]   [Full Text] [Related]  

  • 74. The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
    Button B; Croessmann S; Chu D; Rosen DM; Zabransky DJ; Dalton WB; Cravero K; Kyker-Snowman K; Waters I; Karthikeyan S; Christenson ES; Donaldson J; Hunter T; Dennison L; Ramin C; May B; Roden R; Petry D; Armstrong DK; Visvanathan K; Park BH
    Breast Cancer Res Treat; 2019 Apr; 174(2):401-412. PubMed ID: 30560461
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers.
    Sengupta S; Biarnes MC; Jordan VC
    Breast Cancer Res Treat; 2014 Jan; 143(1):113-24. PubMed ID: 24309997
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer.
    Du J; Zhou N; Liu H; Jiang F; Wang Y; Hu C; Qi H; Zhong C; Wang X; Li Z
    PLoS One; 2012; 7(4):e35957. PubMed ID: 22558281
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients.
    Franken A; Honisch E; Reinhardt F; Meier-Stiegen F; Yang L; Jaschinski S; Esposito I; Alberter B; Polzer B; Huebner H; Fasching PA; Pancholi S; Martin LA; Ruckhaeberle E; Schochter F; Tzschaschel M; Hartkopf AD; Mueller V; Niederacher D; Fehm T; Neubauer H
    J Mol Diagn; 2020 Jan; 22(1):111-121. PubMed ID: 31669227
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus.
    Stossi F; Madak-Erdoğan Z; Katzenellenbogen BS
    Oncogene; 2012 Apr; 31(14):1825-34. PubMed ID: 21860415
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer.
    Xiong S; Song K; Xiang H; Luo G
    Eur J Med Chem; 2024 Apr; 270():116393. PubMed ID: 38588626
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ERα-positive breast cancer cells.
    Zhang Q; Liu XY; Li S; Zhao Z; Li J; Cui MK; Wang EH
    Biochem Biophys Res Commun; 2017 Oct; 492(3):425-433. PubMed ID: 28842253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.